AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$REGN

Guarini Kathryn sold $340K of REGN

Guarini Kathryn sold 400 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $850.00 ($0.34M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guarini Kathryn
Published Sep 3, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

The disclosed sale is a primary source event but modest in scale, offering limited trading edge.

02

Market read

Provides a fresh insider sale data point; limited impact on price expectations.

03

What to watch

Potential upcoming FDA decisions or trial results could outweigh the insider sale signal.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑02

Background

SEC Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

Director Kathryn Guarini sold 400 shares of Regeneron at $850 each, total $340K, via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 0.5‑1% if market reacts.

Evidence & confidence

A $340K sale by a director is a routine liquidity move; not large enough to drive major price action.

Market effects

Sector

Minimal impact on biotech sector; typical insider sales are common.

Regional

No regional effect; confined to Regeneron shareholders.

Global

Negligible on global markets.

Counterpoint

What could challenge this read

If the director is cashing out ahead of upcoming negative news, the sale could foreshadow a drop.

Key entities

  • Company
    Regeneron Pharmaceuticals, Inc.

    Biotech firm developing therapeutics; ticker REGN.

  • Insider
    Kathryn Guarini

    Director of Regeneron, executed a 10b5‑1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REGN insider trading history →

Related articles

OCT 16
$REGNMed

Tricks, treats, and trial results in biotech

A report found 15 biotech companies, including ThermoFisher and MilliporeSigma, manipulated antibody assay images. Regeneron's free gene therapy for hearing loss sparked debate. Novartis faced setbacks with failed trials. FDA introduced fast-track programs for ultra-rare diseases and a PreCheck initiative for drug manufacturing.

bioxconomy.com5 min
OCT 16
$REGNMed

CHMP Backs Less Frequent Regeneron's Libtayo Dosing Across Approved Cancer Indications In Europe

Regeneron (REGN) announced the EMA's CHMP recommended an updated dosing regimen for Libtayo (cemiplimab) across all approved EU indications. The new regimen reduces dosing frequency after 12 weeks. The European Commission will make a final decision in the coming months. Libtayo is approved in over 30 countries for various cancers. REGN stock closed at $769.34, up 2.31%.

rttnews.com2 min
OCT 16
$LLYHigh

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

tradingview.com2 min
OCT 16
$REGNMed

CHMP backs wider dosing gap for Regeneron’s Libtayo

Regeneron Pharmaceuticals (NASDAQ: REGN) announced on 16 October 2026 that the European Medicines Agency's CHMP recommended a less frequent dosing schedule for its cancer drug Libtayo, moving from every three weeks to every six weeks after an initial 12-week period. The change, if approved by the European Commission, would apply across all of Libtayo's approved cancer indications in the EU.

financial-news.co.uk2 min
OCT 16
$REGNMed

EU advisers recommend a 15-minute option for some cancer infusions after a tolerated first dose

Regeneron's Libtayo (cemiplimab) received a positive opinion from the EMA's CHMP for an alternative dosing schedule. The new regimen includes a 700 mg dose every six weeks after an initial 12-week regimen of 350 mg every three weeks, with a potential 15- to 30-minute infusion time for the 350 mg dose. The European Commission is expected to make a final decision in the coming months.

stocktitan.net2 min